Biopolym. Cell. 1998; 14(4):332-342.
Полінуклеотидні інгібітори вірусної репродукції (алкіловані нуклеїнові кислоти, антисенсові РНК та рибозими)
1Швед А. Д.
- Інститут молекулярної біології і генетики НАН України
Вул. Академіка Заболотного, 150, Київ, Україна, 03680
Abstract
В огляді наведено дані власних робіт з вивчення поліну клеотид них інгібіторів вірусної репродукції. На моделях ДНК- та РНК-геномних вірусів показано противірусну активність ряду нуклеїнових кислот з різних природних джерел, а їхні алкіловані похідні виявилися значно ефективнішими інгібіторами вірусної репродукції. Ендогенний синтез антисенсових РНК забезпечував суттєве пригнічення репродукції ВІЛ-1 у культурах гемопоетичних клітин людини. Синтезовано та клоновано рибозим, здатний специфічно розрізати in vitro tat-PHK ВІЛ-I.
Повний текст: (PDF, українською)
References
[1]
Shved AD. [Antiviral properties of polynucleotides not associated with interferon induction]. Mikrobiol Zh. 1982;44(3):75-85.
[2]
Chandra P, Kornhuber B, Ebener U. Biological and clinical effects of a partially thiolated polycytidylic acid (MPC): a potent inhibitor of DNA synthesis in RNA tumor viruses. Haematol Blood Transfus. 1979;23:145-55.
[3]
Pitha PM. Analogues of viral genomes. Selective inhibitors of viral function. Ed. W. A. Carter. Cleveland: CRC press 1973: 394-60.
[4]
Pitha P.M, Pitha J. Polynucleotide analogs as inhibitors of DNA and RNA polymerases. Inhibitors of DNA and RNA polymerases. Ed. P. Sarin, R. Gallo. New York: Pergamor press, 1980: 235-247.
[5]
Shved AD, Spivak AYa, Onishchuk FD et al. Study of the antiviral activity of exogenous nucleic acids, and chemically modified derivatives. Macromolecules of cells and viruses. Kiev. Naukova Dumka, 1986;47-60.
[6]
Shved AD. Structure and functional properties of field nucleotide inhibitors of viral reproduction (alkylated nucleic acids RNA and antisens ribozymes): Author Thesis. ... dr biol nauk. Kyiv, 1996. 43 p.
[7]
Potopal'ski? AI, Spivak NIa, Shved AD, Mel'nichenko VS, Krasnova EF. [The activity of chemical preparations with respect to the transmissible gastroenteritis virus and enterovirus of swine]. Mikrobiol Zh. 1983;45(5):75-8.
[8]
Sela I, Applebaum SW. Occurrence of antiviral factor in virus-infected plants. Virology. 1962;17:543-8.
[9]
Romanova SA, Ledneva VA. The case of natural vaccination potato weak strain X-vie-Virus potatoes (KVC). Theory and practice of use of agricultural immunity crops to viral diseases: Proc. rep. VIII All-Union. conf. Vilnus, 1984;79-80.
[10]
Vlasov YuI, Katin IA. The impact of the vaccine strain of TMV to education antiviral substances in tomato plants. Bull VIZR. 1983;54:85-9.
[11]
Vlasov YuI, Parshin VG. Biological basis and the practical use of induced immunity of plants to pests and diseases. Bull VIZR. 1981; 30:3-5.
[12]
Reyfmaia VG, Romanova SA. Vaccination low pathogenic strain of potato virus X. Theory and practice of use of agricultural immunity crops to viral diseases: Proc. rep. VIII All-Union. meet. Vilnus, 1984;78-9.
[13]
Katin IA. The method of vaccination and antiviral agent. Theory and practice of use of agricultural immunity crops to viral diseases: Proc. rep. VIII All-Union. meet. Vilnus, 1984; 109-11.
[14]
Rodina KI. Stability of tomato to potato virus X, induced by a weak strain. Theory and practice of use of agricultural immunity crops to viral diseases: Proc. rep. VIII All-Union. meet. Vilnus, 1984; 115-7.
[15]
Shved AD, Babkin VF, Potopal'ski? AI, Mel'nichenko VS, Krasnova EF. [Inhibition of the reproduction of the avian infectious laryngotracheitis virus by chemically modified nucleic acids]. Vopr Virusol. 1982;27(3):373-5. Russian.
[16]
Semernikova MI, Didenko LF, Shved AD et al. Latency reproduction potato virus X via homologous virus inactivated. Theory and practice of use of agricultural immunity crops to viral diseases: Proc. rep. VIII All-Union. meet. Vilnus, 1984;23-24.
[17]
Semernikova LI, Didenko LF, Kraev VG, Kitam OE, Shved AD. On the possibility of induction in plants resistance to potato X-virus by alkylated preparations of homologous virus and its RNA. Mikrobiol Z. 1996; 58(6):29-37.
[18]
Shved AD, Solomko AP, Potopalskiya AI et al. Structural and functional properties of modified nucleic acids. Molekulyarnaya Biologiia (Kiev); 1980; (26): 64-78.
[19]
Buzhievskaya TI, Lukash LL, Shved AD, Melnichenko VS. Induction of gene mutations in mammal cells by RNA of influenza virus. Dopovidi Akad Nauk Ukr RSR. Ser B. 1981;(9):63-6.
[20]
Buzhievskaya TI, Lukash LL, Shved AD, Vavilina IV, Melnichenko VS. Mutagenic effect of the native and modified RNA of the influenza virus. Doklady Akad Nauk Ukr SSR. Ser B. 1985;(7):59-61.
[21]
Rubashevski? EL, Lukash LL, Shved VS, Mel'nichenko VS, Tyl'vanchuk LT. [Mutagenic activity of native and inactivated herpes simplex virus]. Nauchnye Doki Vyss Shkoly Biol Nauki. 1988;(9):83-7.
[22]
Stebbing N, Grantham CA, Lindley IJ, Eaton MA, Carey NH. In vivo antiviral activity of polynucleotide mimics of strategic regions in viral RNA. Ann N Y Acad Sci. 1977;284:682-96.
[23]
Mazo AM, Avdonina TA, Mashkova TD, Kisselev LL. Directed cleavage of ribopolynucleotides with nucleases restricted by multiple modification of substrate. Biochim Biophys Acta. 1976;432(3):353-60.
[24]
S?gi J, Otv?s L. Modified polynucleotides. V. Slow-down of nuclease action by 5-alkyluracil-containing DNAs. Biochem Biophys Res Commun. 1980;95(1):156-62.
[25]
Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Hill R, Mortimer J, Neiman PE, Sanders JE, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol. 1987;5(9):1340-7.
[26]
Yamada O, Yu M, Yee JK, Kraus G, Looney D, Wong-Staal F. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther. 1994;1(1):38-45.
[27]
Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell. 1989;59(1):113-20.
[28]
Steffy KR, Wong-Staal F. Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope deletion mutant. J Virol. 1993;67(4):1854-9.
[29]
Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell. 1990;63(3):601-8.
[30]
Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol. 1992;4(1):66-74.
[31]
Malim MH, B?hnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. Cell. 1989;58(1):205-14.
[33]
Kukharenko O, Lukash L, Ivanska YA et al. Construction of eukaryotic vector based on AAV, which makes the synthesis of RNA in the cell antysensovyh HIV. Proc. Ist Nat Sci Pract Conf AIDS. HIV with intr particip (24-26 Jan 1995). Kyiv, 1995;61-2.
[34]
Kukharenko OP, Rybalko SL, Lukash LL et al. [Creating a model vector expressing: Antisense RNA against HIV-1 intracellular immunization for hematopoietic cells]. Infekt Khvorob. 1997; (1):16-20.
[35]
Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992;158:97-129.
[36]
Chatterjee S, Johnson PR, Wong KK Jr. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science. 1992;258(5087):1485-8.
[37]
Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A. 1992;89(15):7257-61.
[38]
Ponnazhagan S, Nallari ML, Srivastava A. Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors. J Exp Med. 1994;179(2):733-8.
[39]
Zhou SZ, Cooper S, Kang LY, Ruggieri L, Heimfeld S, Srivastava A, Broxmeyer HE. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med. 1994;179(6):1867-75.
[40]
Ivanska N, Sukhorada O, Lukash L et al. The sensitivity of human embryonic stem cells to HIV. Proc. Ist Nat Sci Pract Conf AIDS. HIV with intr particip (24-26 Jan 1995). Kyiv:56-57.
[41]
Ivanskaya NV, Lukash LL, Shved AD, Rybalko SL, Sukhorada OM, Zherebtsova EM, Ruban TO, Podolskaya SV, Kukcharenko OP, Grytsak TF, Maksimenok OV. Permissivness of human embryo liver cells for HIV infection. Biopolym Cell. 1997; 13(3):245-9.
[42]
Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996;271(5247):324-8.
[43]
Feng Y, Broder CC, Kennedy PE, Berger EA. Pillars article: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996. 272: 872-877.
[44]
Clapham PR, Weiss RA. Immunodeficiency viruses. Spoilt for choice of co-receptors. Nature. 1997;388(6639):230-1.
[45]
Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. 1997;388(6639):296-300.
[46]
Antoni BA, Rabson AB, Miller IL, Trempe JP, Chejanovsky N, Carter BJ. Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells. J Virol. 1991;65(1):396-404.
[47]
Rittner K, Heilbronn R, Kleinschmidt JA, Sczakiel G. Adeno-associated virus type 2-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) replication: involvement of p78rep/p68rep and the HIV-1 long terminal repeat. J Gen Virol. 1992;73 ( Pt 11):2977-81.
[48]
Oelze I, Rittner K, Sczakiel G. Adeno-associated virus type 2 rep gene-mediated inhibition of basal gene expression of human immunodeficiency virus type 1 involves its negative regulatory functions. J Virol. 1994;68(2):1229-33.
[50]
Forster AC, Symons RH. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell. 1987;49(2):211-20.
[52]
Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 1988;334(6183):585-91.
[53]
Buryanovsky LN, Schved AD. In vitro specific cleavage of HIV-1 tat-RNA by catalytically active polyribonucleotide, ribozyme. Biopolym Cell. 1996; 12(2):20-23.
[54]
Buryanovsky LN, Shved AD. Characterization of catalytic activity in vitro of the ribozyme targeted to tat-RNA of HIV-I. Biopolym Cell. 1996; 12(6):69-73.
[55]
Buryanovsky LN. Effect of pH, ionic strength, and ionic composition on efficiency of hammerhead ribozyme-mediated cleavage of the tat-RNA HIV-I in vitro. Biopolym Cell. 1997; 13(1):30-35.
